• Circulating tumour DNA to evaluate response in children with neuroblastoma

    In the phase 2 NANT2011-01 trial, levels of circulating tumour DNA (ctDNA) were evaluated during treatment. In patients with a clinical response, ctDNA becomes undetectable over time.

  • Post-nephrectomy pembrolizumab improves disease-free survival

    Adjuvant therapy with pembrolizumab after nephrectomy enhances disease-free survival of patients treated for locoregional clear cell RCC.

  • Germany: How digital is medical education?

    Practice-oriented digitisation approaches can already be found in many areas of medicine. But does digitisation play a role in medical education? Survey results show: There is still a lot of catching up to do.

  • Addition of abiraterone to ADT (plus docetaxel) nearly doubles survival of de novo metastatic prostate cancer

    Adding abiraterone to ADT plus docetaxel significantly improves PFS in patients who present de novo mCSPC without meaningful added short-term toxicity according to phase 3 PEACE-1 trial.

  • Novel dual checkpoint blockade improves progression-free survival in melanoma

    Phase 3 RELATIVITY-047 trial results validate the efficacy of dual checkpoint blockade shown with the LAG-3 inhibitor relatlimab and nivolumab in advanced melanoma patients.

  • Immune-related adverse events are associated with efficacy of atezolizumab in patients with advanced NSCLC

    Analysis of phase 3 trials with atezolizumab in stage IV NSCLC patients shows longer overall survival for those experiencing immune-related AEs.

  • Excellent prognosis for breast cancer patients with ultra-low-risk gene signature

    Analysis of 1,000 patients in the MINDACT trial identifies patients with ultra-low risk for distant recurrence. These patients could be candidates for further de-escalation of treatment.

  • Patritumab deruxtecan (HER3-DXd) in EGFR TKI-resistant NSCLC

    Patritumab deruxtecan demonstrates anti-tumour activity across various EGFR TKI resistance mechanisms in heavily pretreated, metastatic/locally advanced, EGFR-mutated NSCLC.

  • Long-term results from ground-breaking melanoma trials

    After initial results over 5 years ago, long-term follow-up data from 3 clinical trials – CheckMate 067, COLUMBUS, and ABC – show a durable and sustained clinical benefit for patients with melanoma.

  • Pembrolizumab benefits survival in MSI-H/dMMR metastastic colorectal cancer

    First-line treatment of patients with MSI-H/dMMR metastatic colorectal cancer (mCRC) with pembrolizumab improves overall survival, but the prespecified threshold for significance was not reached.

  • Ketamine infusion plus psychotherapy: Berlin practice offers alternative treatment for depression

    The method is called "Augmented Psychotherapy" and shows how depression can be treated when psychotherapy and psychopharmacology are combined.

  • Global Outbreak Update: Laboratory-confirmed case of monkeypox in the UK

    The UK notified the WHO of a PCR-confirmed monkeypox case on a patient that lived and worked in Delta State, Nigeria. A second case was confirmed on 31 May 2021.

  • The risks of polypharmacy in rheumatoid arthritis

    Polypharmacy in RA is associated with increased disease activity, an increased risk of serious adverse events (AEs), and a decreased treatment response.

  • Adjuvant chemotherapy does not improve outcome in patients with locally advanced cervical cancer

    The phase 3 OUTBACK trial results do not support the use of adjuvant chemotherapy after chemoradiation in women with locally advanced cervical cancer.

  • Systemic lupus erythematosus: increased risk of severe infection

    Patients with SLE have an increased risk of developing severe infections compared with non-SLE cases. Moreover, 21% of the mortality in SLE is related to these infections.

  • Olaparib benefits early breast cancer patients with BRCA1/2 germline mutation

    A significantly improved invasive disease-free survival in patients with high risk, HER2-negative, germline BRCA1/2-mutated primary breast cancer is found after 1 year of adjuvant treatment with olaparib.

  • Gene-diet interaction associated with the risk of gout

    Adhering to the healthy Dietary Approaches to Stop Hypertension (DASH) diet decreased the risk of gout in women. This effect was more pronounced in genetically predisposed individuals.

  • Venetoclax does not benefit ER-positive, HER2-negative metastatic breast cancer

    Adding the BCL2 inhibitor venetoclax to endocrine therapy does not improve clinical benefit for ER-positive, HER2-negative, locally advanced/metastatic breast cancer patients.

  • Risankizumab meets primary and ranked secondary endpoints in PsA

    Risankizumab treatment leads to better-than-placebo signs and symptoms in active PsA patients with inadequate response or intolerance to 1 or 2 biologic therapies or at least one DMARD therapy.

  • I-O/chemo combo and I-O/I-O combo better than chemotherapy for oesophageal squamous cell cancer

    First phase-3 CheckMate 648 study results demonstrate higher first-line treatment OS with nivolumab + ipilimumab, or nivolumab + chemotherapy, versus chemotherapy only.

  • 4 |
  • 5 |
  • 6 |
  • 7 |
  • 8 |
  • 9 |
  • 10 |
  • 11 |
  • 12 |
  • 13 |
  • 14 |